Restricted accessReview articleFirst published online 2023-11
Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products via the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic Implications
Several therapeutic strategies for cancer treatments have been developed with time, and significant milestones have been achieved recently. However, with these novel therapies, not all cancer types respond and in the responding cancer types only a subset is affected. The failure to respond is principally the result that these cancers develop several mechanisms of resistance. Thus, a focus of current research investigations is to unravel the various mechanisms that regulate resistance and identify suitable targets for new therapeutics.
Recent Advances:
Hence, many human cancer types have been reported to overexpress the inducible nitric oxide synthase (iNOS) and it has been suggested that iNOS/nitric oxide (NO) plays a pivotal role in the regulation of resistance. We have postulated that iNOS overexpression or NO regulates the overexpression of pivotal anti-apoptotic gene products such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma extra large (Bcl-xL), myeloid cell leukemia-1 (Mcl-1), and survivin. In this report, we describe the various mechanisms, transcriptional, post-transcriptional, and post-translational, by which iNOS/NO regulates the expression of the above anti-apoptotic gene products.
Critical Issues:
The iNOS/NO-mediated regulation of the four gene products is not the same with both specific and overlapping pathways. Our findings are, in large part, validated by bioinformatic analyses demonstrating, in several cancers, several direct correlations between the expression of iNOS and each of the four examined anti-apoptotic gene products.
Future Directions:
We have proposed that targeting iNOS may be highly efficient since it will result in the underexpression of multiple anti-apoptotic proteins and shifting the balance toward the proapoptotic gene products and reversal of resistance. Antioxid. Redox Signal. 39, 853–889.
Get full access to this article
View all access options for this article.
References
1.
AbediniMR, QiuQ, YanX, et al.Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene, 2004; 23(42):6997–7004; doi: 10.1038/SJ.ONC.1207925
2.
Abu-SoudHM, GachhuiR, RaushelFM, et al.The ferrous-dioxy complex of neuronal nitric oxide synthase: Divergent effects of l-arginine and tetrahydrobiopterin on its stability. J Biol Chem, 1997; 272:17349–17353
3.
AdamsC, McCarthyHO, CoulterJA, et al.Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med, 2009; 11(2):160–168; doi: 10.1002/jgm.1280
4.
AdamsCM, Clark-GarveyS, PorcuP, et al.Targeting the Bcl-2 family in B cell lymphoma. Front Oncol, 2019; 8:636.
5.
AhmadR, HussainA, AhsanH. Peroxynitrite: Cellular pathology and implications in autoimmunity. J Immunoassay Immunochem, 2019; 40(2):123–138; doi: 10.1080/15321819.2019.1583109
6.
AlagölH, ErdemE, SancakB, et al.Nitric oxide biosynthesis and malondialdehyde levels in advanced breast cancer. Aust N Z J Surg, 1999; 69(9):647–650; doi: 10.1046/1440-1622199901656
7.
AllagnatF, CunhaD, MooreF, et al.Mcl-1 downregulation by pro-inflammatory cytokines and palmitate is an early event contributing to β-cell apoptosis. Cell Death Differ, 2011; 18(2):328–337; doi: 10.1038/cdd.2010.105
8.
AllenJC, TalabF, ZuzelM, et al.c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood, 2011; 117(8):2414–2422; doi: 10.1182/blood-2010-08-301176
9.
AltieriDC, MarchisioPC. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest, 1999; 79(11):1327–1333.
10.
AntonacopoulouAG, FloratouK, BravouV, et al.The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol Dordr, 2011; 34(4):381–391; doi: 10.1007/s13402-011-0038-4
11.
AouacheriaA, BrunetF, GouyM. Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-only, and Bnip families of apoptotic regulators. Mol Biol Evol, 2005; 22(12):2395–2416; doi: 10.1093/MOLBEV/MSI234
12.
AranovichA, LiuQ, CollinsT, et al.Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-xL and Bcl-2 quantified in live MCF-7 cells. Mol Cell, 2012; 45(6):754–763; doi: 10.1016/j.molcel.2012.01.030
13.
AssreuyJ, CunhaFQ, LiewFY, et al.Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol, 1993; 108:833–837.
14.
AzadN, VallyathanV, WangL, et al.S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J Biol Chem, 2006; 281(45):34124–34134; doi: 10.1074/jbc.M602551200
15.
BalakrishnanK, WierdaWG, KeatingMJ, et al.Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 2008; 112(5):1971–1980; doi: 10.1182/blood-2007-12-126946
16.
BalligandJL, Ungureanu-LongroisD, SimmonsWW, et al.Cytokine-inducible nitric oxide synthase (INOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem, 1994; 269(44):27580–27588.
17.
BarrettRMA, OsborneTP, WheatleySP. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle Georget Tex, 2009; 8(2):278–283; doi: 10.4161/cc.8.2.7587
18.
BazakJ, FaheyJM, WawakK, et al.Bystander effects of nitric oxide in anti-tumor photodynamic therapy. Cancer Cell Microenviron, 2017; 4(1):e1511; doi: 10.14800/ccm.1511
19.
BeppuT, NishiK, ImotoS, et al.Novel nitric oxide donor, nitrated phenylbutyrate, induces cell death of human pancreatic cancer cells and suppresses tumor growth of cancer xenografts. Oncol Rep, 2022; 48(4):178; doi: 10.3892/or.2022.8393
20.
BeroukhimR, MermelCH, PorterD, et al.The landscape of somatic copy-number alteration across human cancers. Nature, 2010; 463(7283):899–905; doi: 10.1038/nature08822
21.
BerthelootD, LatzE, FranklinBS. Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell Mol Immunol, 2021; 18(5):1106–1121; doi: 10.1038/s41423-020-00630-3
22.
BessouM, LopezJ, GadetR, et al.The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production. Oncogene, 2020; 39(15):3056–3074; doi: 10.1038/s41388-020-1212-9
23.
BhattacharyaS, RayRM, JohnsonLR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J, 2005; 392(Pt 2):335–344; doi: 10.1042/BJ20050465
24.
BhowmickR, GirottiAW. Cytoprotective signaling associated with nitric oxide upregulation in tumor cells subjected to photodynamic therapy-like oxidative stress. Free Radic Biol Med, 2013; 57:39–48; doi: 10.1016/j.freeradbiomed.2012.12.005
25.
BinjuM, Amaya-PadillaMA, WanG, et al.Therapeutic inducers of apoptosis in ovarian cancer. Cancers, 2019; 11(11):1786; doi: 10.3390/cancers11111786
26.
Bisol Â, de CamposPS, LamersML. Flavonoids as anticancer therapies: A systematic review of clinical trials. Phytother Res, 2020; 34(3):568–582; doi: 10.1002/ptr.6551
27.
BlaineauSV, AouacheriaA. BCL2DB: Moving “helix-bundled” BCL-2 family members to their database. Apoptosis, 2009; 14(7):923–925; doi: 10.1007/S10495-009-0376-0/TABLES/1
28.
BlomberyP, AndersonMA, GongJN, et al.Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov, 2019; 9(3):342–353; doi: 10.1158/2159-8290-18-1119
29.
BoiseLH, González-GarcíaM, PostemaCE, et al.Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 1993; 74(4):597–608; doi: 10.1016/0092-86749390508-
30.
BolomskyA, VoglerM, KöseMC, et al.MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol, 2020; 13(1):173; doi: 10.1186/s13045-020-01007-9
31.
BonavidaB. Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. Biochem Pharmacol, 2020; 176:113913; doi: 10.1016/j.bcp.2020.113913
32.
BoucherMJ, MorissetJ, VachonPH, et al.MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem, 2000; 79(3):355–369.
33.
BradyG, CreanSJ, LorenzonA, et al.IGF-I protects human oral buccal mucosal epithelial cells from sodium nitroprusside-induced apoptosis via PI3-kinase. Growth Horm IGF Res, 2008; 18(4):298–306; doi: 10.1016/j.ghir.2007.11.006
34.
BrattonMR, DuongBN, ElliottS, et al.Regulation of Erα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: Implications for breast cancer cell survival. Int J Oncol, 2010; 37(3):541–550; doi: 10.3892/ijo_00000703
35.
BrentnallM, Rodriguez-MenocalL, De GuevaraRL, et al.Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol, 2013; 14(1):32; doi: 10.1186/1471-2121-14-32
36.
BrownGC, CooperCE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett, 1994; 356(2–3):295–298; doi: 10.1016/0014-5793(94)01290-3
CahuanaGM, TejedoJR, JiménezJ, et al.Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp Cell Res, 2004; 293(1):22–30; doi: 10.1016/j.yexcr.2003.10.004
39.
CampbellKJ, BathML, TurnerML, et al.Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood, 2010; 116(17):3197–3207; doi: 10.1182/BLOOD-2010-04-281071
40.
CampbellKJ, DhayadeS, FerrariN, et al.MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis, 2018; 9(2):19; doi: 10.1038/s41419-017-0035-2
41.
CampbellKJ, LeungHY. Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. Cancer Lett, 2021; 520:213–221; doi: 10.1016/j.canlet.2021.07.045
42.
CampbellKJ, TaitSWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol, 2018; 8(5):180002; doi: 10.1098/rsob.180002
43.
CamposL, RouaultJP, SabidoO, et al.High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 1993; 81(11):3091–3096.
44.
CanalsS, CasarejosMJ, Rodríguez-MartínE, et al.Neurotrophic and neurotoxic effects of nitric oxide on fetal midbrain cultures. J Neurochem, 2001; 76(1):56–68; doi: 10.1046/j.1471-4159.2001.00010.x
45.
CantoniO, GuidarelliA. Indirect mechanisms of DNA strand scission by peroxynitrite. Methods Enzymol, 2008; 440:111–120; doi: 10.1016/S0076-6879(07)00806-3
46.
CaoY, LinY, SunY, et al.Fenretinide regulates macrophage polarization to protect against experimental colitis induced by dextran sulfate sodium. Bioengineered, 2021; 12(1):151–161; doi: 10.1080/21655979.2020.1859259
47.
CapuozzoM, SantorsolaM, BocchettiM, et al.P53: From fundamental biology to clinical applications in cancer. Biology, 2022; 11(9):1325; doi: 10.3390/biology11091325
48.
CastillaC, CongregadoB, ChinchónD, et al.Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology, 2006; 147(10):4960–4967; doi: 10.1210/en.2006-0502
49.
ChangBS, KelekarA, HarrisMH, et al.The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). Mol Cell Biol, 1999; 19(10):6673–6681; doi: 10.1128/MCB.19.10.6673
50.
ChangC-T, HoT-Y, LinH, et al.5-Fluorouracil induced intestinal mucositis via nuclear factor-ΚB activation by transcriptomic analysis and in vivo bioluminescence imaging. PloS One, 2012; 7(3):e31808; doi: 10.1371/journal.pone.0031808
51.
ChanvorachoteP, NimmannitU, LuY, et al.Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem, 2009; 284(41):28476–28484; doi: 10.1074/jbc.M109.050864
52.
ChanvorachoteP, NimmannitU, StehlikC, et al.Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res, 2006; 66(12):6353–6360; doi: 10.1158/0008-5472.CAN-05-4533
53.
ChaoJ-I, KuoP-C, HsuT-S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem, 2004; 279(19):20267–20276; doi: 10.1074/jbc.M312381200
54.
CharlesIG, PalmerRM, HickeryMS, et al.Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A, 1993; 90:11419–11423.
55.
ChenGG, LeeTW, XuH, et al.Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer, 2008; 112(2):372–381; doi: 10.1002/cncr.23166
56.
ChenJ, WangT, XuS, et al.Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway. Eur J Med Chem, 2017a;135:414–423; doi: 10.1016/j.ejmech.2017.04.045
57.
ChenJ, ZhangX, LentzC, et al.miR-193b regulates Mcl-1 in melanoma. Am J Pathol, 2011a;179(5):2162–2168; doi: 10.1016/j.ajpath.2011.07.010
58.
ChenW, LiY, LiJ, et al.Myricetin affords protection against peroxynitrite-mediated DNA damage and hydroxyl radical formation. Food Chem Toxicol, 2011b;49(9):2439–2444; doi: 10.1016/J.FCT.2011.06.066
59.
ChenX, GuW, WangQ, et al.C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC. Oncotarget, 2017b;9(1):668–679; doi: 10.18632/oncotarget.23089
60.
ChenYK, HsuenSS, LinLM. Increased expression of inducible nitric oxide synthase for human oral submucous fibrosis, verrucous hyperplasia, and verrucous carcinoma. Int J Oral Maxillofac Surg, 2002; 31(4):419–422; doi: 10.1054/ijom.2002.0246
61.
CheungCHA, HuangC-C, TsaiF-Y, et al.Survivin—Biology and potential as a therapeutic target in oncology. Onco Targets Ther, 2013; 6:1453–1462; doi: 10.2147/OTT.S33374
62.
ChoHJ, MartinE, XieQW, et al.Inducible nitric oxide synthase: Identification of amino acid residues essential for dimerization and binding of tetrahydrobiopterin. Proc Natl Acad Sci U S A, 1995; 92(25):11514–11518; doi: 10.1073/pnas.92.25.11514
ChoiBH, YoonHS. FKBP38-Bcl-2 interaction: A novel link to chemoresistance. Curr Opin Pharmacol, 2011; 11(4):354–359; doi: 10.1016/J.COPH.2011.04.013
65.
ChoiS, ChenZ, TangLH, et al.Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat Commun, 2016; 7(1):1–13; doi: 10.1038/ncomms10384
66.
ChoudhariSK, ChaudharyM, BagdeS, et al.Nitric oxide and cancer: A review. World J Surg Oncol, 2013; 11:118; doi: 10.1186/1477-7819-11-118
67.
ChuX-Y, ChenL-B, WangJ-H, et al.Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol, 2012; 105(6):520–528; doi: 10.1002/jso.22134
68.
ChungP, CookT, LiuK, et al.Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide, 2003; 8(2):119–126; doi: 10.1016/1089-86030200147-7
69.
ChunhachaP, PongrakhananonV, RojanasakulY, et al.Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells. Am J Physiol Cell Physiol, 2012; 302(9):C1284–C1292; doi: 10.1152/ajpcell.00318.2011
70.
CianiE, GuidiS, BartesaghiR, et al.Nitric oxide regulates cGMP-dependent CAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide. J Neurochem, 2002; 82(5):1282–1289; doi: 10.1046/1471-4159200201080
71.
CiechanoverA, SchwartzAL. The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A, 1998; 95(6):2727–2730; doi: 10.1073/pnas.95.6.2727
72.
Cillero-PastorB, MartinMA, ArenasJ, et al.Effect of nitric oxide on mitochondrial activity of human synovial cells. BMC Musculoskelet Disord, 2011; 12:42; doi: 10.1186/1471-2474-12-42
73.
CinelliMA, DoHT, MileyGP, et al.Inducible nitric oxide synthase: regulation, structure, and inhibition. Med Res Rev, 2020; 40(1):158–189; doi: 10.1002/med.21599
74.
CleeterMW, CooperJM, Darley-UsmarVM, et al.Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett, 1994; 345(1):50–54; doi: 10.1016/0014-57939400424-2
75.
ClementiE, BrownGC, FeelischM, et al.Persistent inhibition of cell respiration by nitric oxide: Crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A, 1998; 95(13):7631–7636; doi: 10.1073/pnas.95.13.7631
76.
CobbsCS, BrenmanJE, AldapeKD, et al.Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res, 1995; 55(4):727–730.
77.
CohenC, LohmannCM, CotsonisG, et al.Survivin expression in ovarian carcinoma: Correlation with apoptotic markers and prognosis. Mod Pathol, 2003; 16(6):574–583; doi: 10.1097/01.MP.0000073868.31297.B0
78.
Correa-AragundeN, ForesiN, LamattinaL. Structure diversity of nitric oxide synthases (NOS): The emergence of new forms in photosynthetic organisms. Front Plant Sci, 2013; 4:232; doi: 10.3389/fpls.2013.00232
79.
CorreiaC, SchneiderPA, DaiH, et al.BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015; 125(4):658–667; doi: 10.1182/blood-2014-04-571786
80.
CoryS, AdamsJM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer, 2002; 2(9):647–656; doi: 10.1038/nrc883
81.
CossuF, MilaniM, MastrangeloE, et al.Targeting the BIR domains of inhibitor of apoptosis (IAP) proteins in cancer treatment. Comput Struct Biotechnol J, 2019; 17:142–150; doi: 10.1016/j.csbj.2019.01.009
82.
CrawfordM, BatteK, YuL, et al.MicroRNA 133B targets prosurvival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun, 2009; 388(3):483–489; doi: 10.1016/j.bbrc.2009.07.143
83.
CrowellJA, SteeleVE, SigmanCC, et al.Is inducible nitric oxide synthase a target for chemoprevention?. Mol Cancer Ther, 2003; 2(8):815–823.
84.
CuconatiA, MukherjeeC, PerezD, et al.DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev, 2003; 17(23):2922–2932; doi: 10.1101/gad.1156903
85.
CzabotarPE, LesseneG, StrasserA, et al.Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol, 2014; 15(1):49–63; doi: 10.1038/nrm3722
86.
D'AguannoS, Del BufaloD. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: Current overview in cancer. Cells, 2020; 9(5):1287; doi: 10.3390/cells9051287
87.
D'ArcyMS. Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int, 2019; 43(6):582–592; doi: 10.1002/cbin.11137
88.
DashPR, CartwrightJE, BakerPN, et al.Nitric oxide protects human extravillous trophoblast cells from apoptosis by a cyclic GMP-dependent mechanism and independently of caspase 3 nitrosylation. Exp Cell Res, 2003; 287(2):314–324; doi: 10.1016/0014-48270300156-3
89.
DashR, AzabB, QuinnBA, et al.Apogossypol derivative BI-97C1 (sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to MDA-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A, 2011; doi: 10.1073/pnas.1100769108
90.
de JongY, MondererD, BrandinelliE, et al.Bcl-xL as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. Oncogenesis, 2018; 7(9):74; doi: 10.1038/s41389-018-0084-0
91.
de Necochea-CampionR, ChenCS, MirshahidiS, et al.Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett, 2013; 339(2):167–174; doi: 10.1016/J.CANLET.2013.06.007
92.
DebatinK-M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother, 2004; 53(3):153–159; doi: 10.1007/s00262-003-0474-8
93.
DeoraAA, WinT, VanhaesebroeckB, et al.A redox-triggered Ras-effector interaction. Recruitment of phosphatidylinositol 3’-kinase to Ras by redox stress. J Biol Chem, 1998; 273(45):29923–29928; doi: 10.1074/jbc.273.45.29923
94.
DingZ, OgataD, RoszikJ, et al.INOS associates with poor survival in melanoma: A role for nitric oxide in the PI3K-AKT pathway stimulation and PTEN S-nitrosylation. Front Oncol, 2021; 11:631766; doi: 10.3389/fonc.2021.631766
DoronzoG, VirettoM, RussoI, et al.Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress. Atherosclerosis, 2011; 216(1):44–53; doi: 10.1016/j.atherosclerosis.2011.01.019
97.
DuanY-F, SunD-L, ChenJ, et al.MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. Oncol Lett, 2017; 13(3):1775–1782; doi: 10.3892/ol.2017.5623
98.
DudekH, DattaSR, FrankeTF, et al.Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 1997; 275(5300):661–665; doi: 10.1126/science.275.5300.661
99.
DunnePD, ColemanHG, BankheadP, et al.Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget, 2018; 9(17):13834; doi: 10.18632/ONCOTARGET.24481
100.
ElmoreS. Apoptosis: A review of programmed cell death. Toxicol Pathol, 2007; 35(4):495–516; doi: 10.1080/01926230701320337
101.
ElnemrA, OhtaT, YachieA, et al.Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol, 2001; 18(2):311–316; doi: 10.3892/ijo.18.2.311
102.
EngelsK, KnauerSK, LoiblS, et al.NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res, 2008; 68(13):5159–5166; doi: 10.1158/0008-5472.CAN-08-0406
103.
ErlandssonMC, AnderssonKME, OparinaNY, et al.Survivin promotes a glycolytic switch in CD4+ T cells by suppressing the transcription of PFKFB3 in rheumatoid arthritis. iScience, 2022; 25(12):105526; doi: 10.1016/j.isci.2022.105526
104.
FabregatI, RonceroC, FernándezM. Survival and apoptosis: A dysregulated balance in liver cancer. Liver Int, 2007; 27(2):155–162; doi: 10.1111/J.1478-3231.2006.01409.X
105.
FangL, YangN, MaJ, et al.MicroRNA-1301-mediated inhibition of tumorigenesis. Oncol Rep, 2012; 27(4):929–934; doi: 10.3892/or.2011.1589
106.
FantappièO, SassoliC, TaniA, et al.Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane. J Cell Mol Med, 2015; 19(6):1410–1417; doi: 10.1111/jcmm.12528
FernándezY, EspañaL, MañasS, et al.Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ, 2000; 7(4):350–359; doi: 10.1038/sj.cdd.4400662
109.
FernandoV, ZhengX, WaliaY, et al.S-nitrosylation: An emerging paradigm of redox signaling. Antioxidants, 2019; 8(9):404; doi: 10.3390/antiox8090404
110.
FetzV, BierC, HabtemichaelN, et al.Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer, 2009; 124(9):2033–2041; doi: 10.1002/ijc.24182
111.
FisherTC, MilnerAE, GregoryCD, et al.Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res, 1993; 53(14):3321–3326.
112.
ForresterK, AmbsS, LupoldSE, et al.Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A, 1996; 93(6):2442–2447; doi: 10.1073/pnas.93.6.2442.
FrenchLE, TschoppJ. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med, 1999; 190(7):891–894; doi: 10.1084/jem.190.7.891
115.
FrenzelA, GrespiF, ChmelewskijW, et al.Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis, 2009; 14(4):584; doi: 10.1007/S10495-008-0300-Z
116.
FuD, PfannenstielL, DemelashA, et al.MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma. Cell Death Dis, 2022; 13(1):1–11; doi: 10.1038/s41419-021-04334-y
117.
FungS, KnoefelWT, KriegA. Clinicopathological and prognostic significance of inhibitor of apoptosis protein (IAP) family members in lung cancer: A meta-analysis. Cancers, 2021; 13(16):4098; doi: 10.3390/cancers13164098
118.
GabelliniC, CastelliniL, TrisciuoglioD, et al.Involvement of nuclear factor-kappa B in Bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem, 2008; 107(3):871–882; doi: 10.1111/j.1471-4159.2008.05661.x
119.
GabelliniC, Gómez-AbenzaE, Ibáñez-MoleroS, et al.Interleukin 8 mediates Bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. Int J Cancer, 2018; 142(3):584–596; doi: 10.1002/ijc.31075
120.
GaoJ, LiL, WuM, et al.MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One, 2013; 8(6):e65138; doi: 10.1371/journal.pone.0065138
121.
García-ArandaM, Pérez-RuizE, RedondoM. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci, 2018; 19(12):3950; doi: 10.3390/ijms19123950
122.
GargH, SuriP, GuptaJC, et al.Survivin: A unique target for tumor therapy. Cancer Cell Int, 2016; 16(1):49; doi: 10.1186/s12935-016-0326-1
123.
GarridoP, ShalabyA, WalshEM, et al.Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget, 2017; 8(46):80568–80588; doi: 10.18632/oncotarget.19631
124.
Gąsowska-BajgerB, Gąsowska-BodnarA, KnappP, et al.Prognostic significance of survivin expression in patients with ovarian carcinoma: A meta-analysis. J Clin Med, 2021; 10(4):879; doi: 10.3390/jcm10040879
125.
GazzanigaP, GradiloneA, VercilloR, et al.Bcl-2/Bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer, 1996; 69(2):100–104; doi: 10.1002/(SICI)1097-0215(19960422)69:2
126.
GellerDA, NusslerAK, SilvioM, et al.Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A, 1993; 90:522–526.
127.
GenaroAM, HortelanoS, AlvarezA, et al.Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest, 1995; 95(4):1884–1890; doi: 10.1172/JCI117869
128.
GermainM, MilburnJ, DuronioV. MCL-1 inhibits BAX in the absence of MCL-1/BAX interaction. J Biol Chem, 2008; 283(10):6384–6392; doi: 10.1074/jbc.M707762200
129.
Gil-KulikP, KrzyżanowskiA, DudzińskaE, et al.Potential involvement of BIRC5 in maintaining pluripotency and cell differentiation of human stem cells. Oxid Med Cell Longev, 2019; 2019:8727925; doi: 10.1155/2019/8727925
130.
GiorginiS, TrisciuoglioD, GabelliniC, et al.Modulation of Bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res, 2007; 5(8):761–771; doi: 10.1158/1541-7786.MCR-07-0088
131.
GlickmanMS, SawyersCL. Converting cancer therapies into cures: Lessons from infectious diseases. Cell, 2012; 16;148(6):1089–1098; doi: 10.1016/j.cell.2012.02.015
132.
GoYM, PatelRP, MalandMC, et al.Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. Am J Physiol, 1999; 4:1647–1653; doi: 10.1152/ajpheart.1999.277.4.H1647
133.
GoldarS, KhanianiMS, DerakhshanSM, et al.Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev, 2015; 16(6):2129–2144; doi: 10.7314/apjcp.2015.16.6.2129
134.
GongJ, ZhangJ-P, LiB, et al.MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene, 2013; 32(25):3071–3079; doi: 10.1038/onc.2012.318
135.
GorabiAM, KiaieN, HajighasemiS, et al.Statin-induced nitric oxide signaling: Mechanisms and therapeutic implications. J Clin Med, 2019; 8(12):2051; doi: 10.3390/jcm8122051
136.
GottesmanMM, PastanIH. The role of multidrug resistance efflux pumps in cancer: Revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer Inst, 2015; 107(9):djv222; doi: 10.1093/jnci/djv222
137.
GottschalkAR, BoiseLH, ThompsonCB, et al.Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by Bcl-x but not Bcl-2. Proc Natl Acad Sci U S A, 1994; 91(15):7350–7354; doi: 10.1073/pnas.91.15.7350
138.
Granados-PrincipalS, LiuY, GuevaraML, et al.Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res, 2015; 17(1):25; doi: 10.1186/s13058-015-0527-x
139.
GreenDR, EvanGI. A matter of life and death. Cancer Cell, 2002; 1(1):19–30; doi: 10.1016/s1535-6108(02)00024-7
140.
GuM, ZhengW, ZhangM, et al.lncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through P-CREB/Bcl-2 apoptosis signaling pathway in breast cancer. J Cancer, 2020; 11(12):3645–3654; doi: 10.7150/jca.39463
141.
GuptaVA, AckleyJ, KaufmanJL, et al.BCL2 family inhibitors in the biology and treatment of multiple myeloma. Blood Lymphat Cancer Targets Ther, 2021; 11:11–24; doi: 10.2147/BLCTT.S245191
142.
GurbuxaniS, XuY, KeerthivasanG, et al.Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A, 2005; 102(32):11480–11485; doi: 10.1073/pnas.0500303102
143.
HabibS, AliA. Biochemistry of nitric oxide. Indian J Clin Biochem, 2011; 26(1):3–17; doi: 10.1007/s12291-011-0108-4
144.
HäckerG. The morphology of apoptosis. Cell Tissue Res, 2000; 301(1):5–17; doi: 10.1007/s004410000193
145.
HanL, LuY, WangX, et al.Regulatory role and mechanism of the inhibition of the Mcl-1 pathway during apoptosis and polarization of H37Rv-infected macrophages. Medicine (Baltimore), 2020; 99(42):e22438; doi: 10.1097/MD.0000000000022438
146.
HanX, ChenH, ZhouJ, et al.Pharmacological inhibition of p38 MAPK by SB203580 increases resistance to carboplatin in A2780cp cells and promotes growth in primary ovarian cancer cells. Int J Mol Sci, 2018; 19(8):2184; doi: 10.3390/ijms19082184
147.
HartmanML, CzyzM. Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett, 2013; 331(1):24–34; doi: 10.1016/j.canlet.2013.01.010
148.
HaselagerM, ThijssenR, WestC, et al.Regulation of Bcl-xL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Cell Death Differ, 2021; 28(5):1658–1668; doi: 10.1038/s41418-020-00692-w
149.
HengartnerMO. Apoptosis: Corralling the corpses. Cell, 2001; 104(3):325–328; doi: 10.1016/0092-86740100219-7
150.
Hernandez-LunaMA, Rocha-ZavaletaL, VegaMI, et al.Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. Leuk Lymphoma, 2013; 54(5):1048–1055; doi: 10.3109/10428194.2012.733874
151.
Hernansanz-AgustínP, Izquierdo-ÁlvarezA, García-OrtizA, et al.Nitrosothiols in the immune system: Signaling and protection. Antioxid Redox Signal, 2013; 18:288–308.
152.
HickokJR, ThomasDD. Nitric oxide and cancer therapy: The emperor has NO clothes. Curr Pharm Des, 2010; 16(4):381–391; doi: 10.2174/138161210790232149
153.
HindsMG, NortonRS, VauxDL, et al.Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat Struct Biol, 1999; 6(7):648–651; doi: 10.1038/10701
154.
HindsMG, SmitsC, Fredericks-ShortR, et al.Bim, Bad and Bmf: Intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ, 2007; 14(1):128–136; doi: 10.1038/SJ.CDD.4401934
155.
HoW-P, ChanW-P, HsiehM-S, et al.Runx2-mediated Bcl-2 gene expression contributes to nitric oxide protection against hydrogen peroxide-induced osteoblast apoptosis. J Cell Biochem, 2009; 108(5):1084–1093; doi: 10.1002/jcb.22338
156.
HockenberyD, NuñezG, MillimanC, et al.Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990; 348(6299):334–336; doi: 10.1038/348334a0
HolotiukVV, KryzhanivskaAY, ChurpiyIK, et al.Role of nitric oxide in pathogenesis of tumor growth and its possible application in cancer treatment. Exp Oncol, 2019; 41(3):210–215; doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13515
159.
HosseiniA, KoskelaLR, EhrénI, et al.Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. Nitric Oxide Biol Chem, 2006; 15(4):337–343; doi: 10.1016/j.niox.2006.01.007
160.
HuX, WangJ, ChuM, et al.Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy. Mol Ther, 2021; 29(3):908–919; doi: 10.1016/j.ymthe.2020.12.032
161.
HuangJ, TatsumiT, PizzoferratoE, et al.Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res, 2005; 65(18):8461–8470; doi: 10.1158/0008-5472-05-0654
162.
HuangK, LiLA, MengYG, et al.Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling. Basic Clin Pharmacol Toxicol, 2014a;115(6):507–511; doi: 10.1111/bcpt.12270
163.
HuangZ, FuJ, ZhangY. Nitric oxide donor-based cancer therapy: Advances and prospects. J Med Chem, 2017; 60(18):7617–7635; doi: 10.1021/acs.jmedchem.6b01672
164.
HuangZ, LiuC-A, CaiP-Z, et al.Omega-3PUFA attenuates MNU-induced colorectal cancer in rats by blocking PI3K/AKT/Bcl-2 signaling. Onco Targets Ther, 2020; 13:1953–1965; doi: 10.2147/OTT.S241298
165.
HuangZ-M, ChenH-A, ChiangY-T, et al.Association of polymorphisms in INOS and NQO1 with bladder cancer risk in cigarette smokers. J Chin Med Assoc, 2014b;77(2):83–88; doi: 10.1016/j.jcma.2013.10.005
166.
Huerta-YepezS, BaritakiS, Baay-GuzmanG, et al.Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. Nitric Oxide Biol Chem, 2013; 29:17–24; doi: 10.1016/j.niox.2012.12.001
167.
Huerta-YepezS, VegaM, JazirehiA, et al.Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-Kappa B and inhibition of Bcl-xL expression. Oncogene, 2004; 23(29):4993–5003; doi: 10.1038/sj.onc.1207655
168.
InoshitaS, TakedaK, HataiT, et al.Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem, 2002; 277(46):43730–43734; doi: 10.1074/jbc.M207951200
169.
IyerAKV, AzadN, WangL, et al.Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide, 2008; 19(2):146–151; doi: 10.1016/j.niox.2008.04.019
170.
JaiswalPK, GoelA, MittalRD. Survivin: A molecular biomarker in cancer. Indian J Med Res, 2015; 141(4):389–397; doi: 10.4103/0971-5916.159250
171.
JanR, ChaudhryG-S. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull, 2019; 9(2):205–218; doi: 10.15171/apb.2019.024
172.
JanakiramNB, RaoCV. INOS-selective inhibitors for cancer prevention: Promise and progress. Future Med Chem, 2012; 4(17):2193–2204; doi: 10.4155/fmc.12.168
173.
JiQ, HaoX, ZhangM, et al.microRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. pLoS One, 2009; 4(8):e6816; doi: 10.1371/journal.pone.0006816
174.
JiangJ, LiuJ, ZhuJ, et al.Mechanism of apoptotic effects induced by 5-fluorouracil on human liver carcinoma Bel7402 cell line. Chin Med J (Engl), 2002; 115(7):968–971.
175.
JiangM-C, NiJ-J, CuiW-Y, et al.Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res, 2019; 9(7):1354.
176.
JiangSX, SatoY, KuwaoS, et al.Expression of Bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol, 1995; 177(2):135–138; doi: 10.1002/path.1711770206
177.
JoensuuH, PylkkänenL, ToikkanenS. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol, 1994; 145(5):1191–1198.
178.
JourdainA, MartinouJ-C. Mitochondrial outer-membrane permeabilization and remodelling in apoptosis. Int J Biochem Cell Biol, 2009; 41(10):1884–1889; doi: 10.1016/j.biocel.2009.05.001
179.
JuangSH, XieK, XuL, et al.Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma. Cancer Biother Radiopharm, 1997; 12(3):167–175; doi: 10.1089/cbr.1997.12.167
180.
KaleJ, OsterlundEJ, AndrewsDW. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ, 2018; 25(1):65–80; doi: 10.1038/cdd.2017.186
181.
KanugulaAK, GollavilliPN, VasamsettiSB, et al.Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: Intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J, 2014; 281(16):3719–3738; doi: 10.1111/febs.12893
182.
KapoorI, BodoJ, HillBT, et al.Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis, 2020; 11(11):1–11; doi: 10.1038/s41419-020-03144-y
183.
KarakasT, MaurerU, WeidmannE, et al.High expression of Bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol, 1998; 9(2):159–165; doi: 10.1023/A:1008255511404
184.
KarinM, LinA. NF-kappaB at the crossroads of life and death. Nat Immunol, 2002; 3(3):221–227; doi: 10.1038/0302-221
185.
KaufmannSH, DesnoyersS, OttavianoY, et al.Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res, 1993; 53(17):3976–3985.
186.
KaufmannSH, KarpJE, SvingenPA, et al.Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 1998; 91(3):991–1000.
187.
KawanishiS, OhnishiS, MaN, et al.Crosstalk between DNA damage and inflammation in the multiple steps of carcinogenesis. Int J Mol Sci, 2017; 18(8):1808; doi: 10.3390/ijms18081808
188.
KawasakiK, RSSJr, HsiehCM, et al.Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol, 2003; 23(16):5726–5737; doi: 10.1128/MCB.23.16.5726-5737.2003
189.
KerrJF, WinterfordCM, Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994; 73(8):2013–2026; doi: 10.1002/1097-0142(19940415)73:8
190.
KerrJFR, WyllieAH, CurrietAR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972; 26:239.
191.
KhanAQ, AhmedEI, ElareerNR, et al.Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells, 2019; 8(8):840; doi: 10.3390/CELLS8080840
192.
KhanFH, DervanE, BhattacharyyaDD, et al.The role of nitric oxide in cancer: Master regulator or nOt?. Int J Mol Sci, 2020; 21(24):9393; doi: 10.3390/ijms21249393
193.
KhanSA, BurkeM, ZhuF, et al.Survivin expression and impact on head and neck cancer outcomes. Oral Oncol, 2021; 112:105049; doi: 10.1016/j.oraloncology.2020.105049
194.
KielbikM, Szulc-KielbikI, KlinkM. The potential role of iNOS in ovarian cancer progression and chemoresistance. Int J Mol Sci, 2019; 20(7):1751; doi: 10.3390/ijms20071751
195.
KimJ, WonJS, SinghAK, et al.STAT3 regulation by S-nitrosylation: Implication for inflammatory disease. Antioxid Redox Signal, 2014; 20(16):2514–2527; doi: 10.1089/ars.2013.5223
196.
KimJ-E, TannenbaumSR. S-nitrosation regulates the activation of endogenous procaspase-9 in HT-29 human colon carcinoma cells. J Biol Chem, 2004; 279(11):9758–9764; doi: 10.1074/jbc.M312722200
197.
KimJH, SimSH, HaHJ, et al.MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. FEBS Lett, 2009; 583(17):2758–2764; doi: 10.1016/j.febslet.2009.08.006
198.
KimPK, ZamoraR, PetroskoP, et al.The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol, 2001; 1(8):1421–1441; doi: 10.1016/s1567-5769(01)00088-1
199.
KimYM, KimTH, SeolDW, et al.Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem, 1998; 273(47):31437–31441; doi: 10.1074/jbc.273.47.31437
200.
KitadaS, ZapataJM, AndreeffM, et al.Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 2000; 96(2):393–397.
201.
KleinertH, PautzA, LinkerK, et al.Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol, 2004; 500(1–3):255–266; doi: 10.1016/j.ejphar.2004.07.030
202.
KlotzT, BlochW, VolbergC, et al.Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer, 1998; 82(10):1897–1903.
203.
KnightT, LuedtkeD, EdwardsH, et al.A delicate balance—The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol, 2019; 162:250–261; doi: 10.1016/j.bcp.2019.01.015
204.
KoideM, KawaharaY, TsudaT, et al.Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells. FEBS Lett, 1993; 318:213–217.
205.
KojimaM, MorisakiT, TsukaharaY, et al.Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol, 1999; 70(4):222–229; doi: 10.1002/(sici)1096-9098(199904)70:4<222::aid-jso5>3.0.co;2-g
206.
KoneB, KuncewiczT, ZhangW, et al.Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol, 2003; 285:F178–F190.
207.
KoprowskiH, ZhengYM, Heber-KatzE, et al.In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A, 1993; 90:3024–3027.
208.
KotamrajuS, WilliamsCL, KalyanaramanB. Statin-induced breast cancer cell death: Role of inducible nitric oxide and arginase-dependent pathways. Cancer Res, 2007; 67(15):7386–7394; doi: 10.1158/0008-5472.CAN-07-0993
209.
KozopasKM, YangT, BuchanHL, et al.MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A, 1993; 90(8):3516–3520; doi: 10.1073/pnas.90.8.3516
210.
KrajewskiS, BodrugS, KrajewskaM, et al.Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol, 1995; 146(6):1309–1319.
211.
KrólM, KepinskaM. Human nitric oxide synthase—Its functions, polymorphisms, and inhibitors in the context of inflammation, diabetes and cardiovascular diseases. Int J Mol Sci, 2021; 22(1):56; doi: 10.3390/ijms22010056
212.
KruideringM, EvanGI. Caspase-8 in apoptosis: The beginning of “the end”?. IUBMB Life, 2000; 50(2):85–90; doi: 10.1080/713803693
213.
KulikG, KlippelA, WeberMJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol, 1997; 17(3):1595–1606; doi: 10.1128/MCB.17.3.1595
214.
LandesT, MartinouJ-C. Mitochondrial outer membrane permeabilization during apoptosis: The role of mitochondrial fission. Biochim Biophys Acta BBA Mol Cell Res, 2011; 1813(4):540–545; doi: 10.1016/j.bbamcr.2011.01.021
215.
LeX, WeiD, HuangS, et al.Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A, 2005; 102(24):8758–8763; doi: 10.1073/pnas.0409581102
216.
LechnerM, LirkP, RiederJ. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol, 2005; 15(4):277–289; doi: 10.1016/J.SEMCANCER.2005.04.004
217.
LeeDH, PfeiferGP. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis, 2007; 22(1):63–67; doi: 10.1093/mutage/gel051
218.
LeeEF, FairlieWD. The structural biology of Bcl-xL. Int J Mol Sci, 2019; 20(9):2234; doi: 10.3390/ijms20092234
219.
LeeEF, HarrisTJ, TranS, et al.BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis, 2019; 10(5):1–14; doi: 10.1038/s41419-019-1568-3
220.
LeeW-S, KimN, ParkY-R, et al.Myeloid cell leukemia-1 promotes epithelial-mesenchymal transition of human gastric cancer cells. Oncol Rep, 2015; 34(2):1011–1016; doi: 10.3892/or.2015.4040
221.
LeiterU, SchmidRM, KaskelP, et al.Antiapoptotic Bcl-2 and Bcl-xL in advanced malignant melanoma. Arch Dermatol Res, 2000; 292(5):225–232; doi: 10.1007/s004030050479
222.
LeungCG, XuY, MularskiB, et al.Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med, 2007; 204(7):1603–1611; doi: 10.1084/jem.20062395
223.
LeversonJD, CojocariD. Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: A product of its microenvironment?. Front Oncol, 2018; 8:458; doi: 10.3389/fonc.2018.00458
224.
LiF, AckermannEJ, BennettCF, et al.Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol, 1999; 1(8):461–466; doi: 10.1038/70242
225.
LiK, YouT, ZhaoP, et al.Structural basis for the regulation of inducible nitric oxide synthase by the SPRY domain-containing SOCS box protein SPSB2, an E3 ubiquitin ligase. Nitric Oxide, 2021; 113–114:1–6; doi: 10.1016/j.niox.2021.04.004
226.
LiL-G, XuH-M. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol, 2005; 11(17):2539–2544; doi: 10.3748/wjg.v11.i17.2539
227.
LiM. The role of p53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis, 2021; 26(5):235–247; doi: 10.1007/s10495-021-01667-z
228.
LiW, HanW, MaY, et al.p53-Dependent miRNAs mediate nitric oxide-induced apoptosis in colonic carcinogenesis. Free Radic Biol Med, 2015; 85:105–113; doi: 10.1016/j.freeradbiomed.2015.04.016
229.
LiX, HouY, ZhaoJ, et al.Combination of chemotherapy and oxidative stress to enhance cancer cell apoptosis. Chem Sci, 2020; 11(12):3215–3222; doi: 10.1039/C9SC05997K
230.
LiX, ShangB, LiY, et al.IFNγ and TNFα synergistically induce apoptosis of mesenchymal stem/stromal cells via the induction of nitric oxide. Stem Cell Res Ther, 2019a;10(1):18; doi: 10.1186/s13287-018-1102-z
231.
LiX, ZhouJ, WenX, et al.Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. Onco Targets Ther, 2019b;12:3295–3304; doi: 10.2147/OTT.S194549
232.
LiangY, LiE, ZhangH, et al.Silencing of lncRNA UCA1 curbs proliferation and accelerates apoptosis by repressing SIRT1 signals by targeting miR-204 in pediatric AML. J Biochem Mol Toxicol, 2020; 34(3):e22435; doi: 10.1002/jbt.22435
233.
LiaoW, YeT, LiuH. Prognostic value of inducible nitric oxide synthase (iNOS) in human cancer: A systematic review and meta-analysis. Biomed Res Int, 2019; 2019:6304851; doi: 10.1155/2019/6304851
234.
LikuiW, QunL, WanqingZ, et al.Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol, 2009; 100(5):396–400; doi: 10.1002/jso.21344
235.
LinK, BaritakiS, VivarelliS, et al.The breast cancer protooncogenes HER2, BRCA1 and BRCA2 and their regulation by the iNOS/NOS2 axis. Antioxidants, 2022; 11(6):1195; doi: 10.3390/antiox11061195
236.
LindenboimL, BornerC, SteinR. Bcl-xS can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-xS to the mitochondria and its BH3 and loop domains. Cell Death Differ, 2001; 8(9):933–942; doi: 10.1038/SJ.CDD.4400888
237.
LiuFT, NewlandAC, JiaL. Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem Biophys Res Commun, 2003; 310(3):956–962; doi: 10.1016/j.bbrc.2003.09.109
238.
LiuH, SuD, ZhangJ, et al.Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci Rep, 2017; 7(1):8953; doi: 10.1038/s41598-017-09518-1
239.
LiuX, ZhangY, WangY, et al.Protein phosphorylation in cancer: Role of nitric oxide signaling pathway. Biomolecules, 2021; 11(7):1009; doi: 10.3390/biom11071009
240.
LiuY, HernandezAM, ShibataD, et al.BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A, 1994; 91(19):8910–8914; doi: 10.1073/pnas.91.19.8910
241.
LiuY, WangL, ZhaoL, et al.Structure, properties of gossypol and its derivatives-from physiological activities to drug discovery and drug design. Nat Prod Rep, 2022; 39(6):1282–1304; doi: 10.1039/d1np00080b
242.
LiuZ, ZhangYY, ZhangQW, et al.3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway. Anticancer Drugs, 2014; 25(4):447–455; doi: 10.1097/CAD.0000000000000081
243.
LochmannTL, FlorosKV, NaseriM, et al.Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. Clin Cancer Res, 2018; 24(2):360–369; doi: 10.1158/1078-0432.CCR-17-1606
244.
LoftusLV, AmendSR, PientaKJ. Interplay between cell death and cell proliferation reveals new strategies for cancer therapy. Int J Mol Sci, 2022; 23(9):4723; doi: 10.3390/ijms23094723
245.
LoiblS, MinckwitzG, WeberS, et al.Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer, 2002; 95(6):1191–1198; doi: 10.1002/cncr.10817
246.
LotemJ. Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood, 1992; 80(7):1750–757.
247.
LucianòAM, Pérez-OlivaAB, MuleroV, et al.Bcl-xL: A focus on melanoma pathobiology. Int J Mol Sci, 2021; 22(5):2777; doi: 10.3390/ijms22052777
248.
MaJ, ZhaoZ, WuK, et al.MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. Gene, 2016; 587(2):147–154; doi: 10.1016/j.gene.2016.04.054
249.
MaS, LeeTK, ZhengBJ, et al.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008; 27(12):1749–1758; doi: 10.1038/sj.onc.1210811
250.
MaaS-H, WangC-H, LiuC-Y, et al.Endogenous nitric oxide downregulates the Bcl-2 expression of eosinophils through mitogen-activated protein kinase in bronchial asthma. J Allergy Clin Immunol, 2003; 112(4):761–767; doi: 10.1016/S0091-6749(03)02009-8
251.
MackenzieGG, AdamoAM, DeckerNP, et al.Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations. Biochem Pharmacol, 2008; 75(7):1461–1471; doi: 10.1016/j.bcp.2007.12.013
252.
MacMickingJ, XieQW, NathanC. Nitric oxide and macrophage function. Annu Rev Immunol, 1997; 15:323–335.
253.
MacnaulKL, HutchinsonNI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun, 1993; 196:1330–1334.
254.
MaetaY, TsujitaniS, MatsumotoS, et al.Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer, 2004; 7(2):78–84; doi: 10.1007/s10120-004-0272-9
255.
MajiS, PandaS, SamalSK, et al.Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res, 2018; 137:37–75; doi: 10.1016/BS.ACR.2017.11.001
256.
MannickJB, SchonhoffC, PapetaN, et al.S-nitrosylation of mitochondrial caspases. J Cell Biol, 2001; 154(6):1111–1116; doi: 10.1083/jcb.200104008
257.
Martínez-EscardóL, AlemanyM, Sánchez-OsunaM, et al.Gossypol treatment restores insufficient apoptotic function of DFF40/CAD in human glioblastoma cells. Cancers, 2021; 13(21):5579; doi: 10.3390/cancers13215579
258.
Martínez-GarcíaD, Manero-RupérezN, QuesadaR, et al.Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev, 2019; 39(3):887–909; doi: 10.1002/med.21547
259.
Martínez-SifuentesMA, Bassol-MayagoitiaS, Nava-HernándezMP, et al.Survivin in breast cancer: A review. Genet Test Mol Biomark, 2022; 26(9):411–421; doi: 10.1089/gtmb.2021.0286
260.
MarusawaH, MatsuzawaS-I, WelshK, et al.HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J, 2003; 22(11):2729–2740; doi: 10.1093/emboj/cdg263
261.
McCarthyHO, ZholobenkoAV, WangY, et al.Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy. Int J Pharm, 2011; 405(1):196–202; doi: 10.1016/j.ijpharm.2010.11.051
262.
McDonnellTJ, TroncosoP, BrisbaySM, et al.Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res, 1992; 52(24):6940–6944.
263.
MehrotraS, LanguinoLR, RaskettCM, et al.IAP regulation of metastasis. Cancer Cell, 2010; 17(1):53–64; doi: 10.1016/j.ccr.2009.11.021
264.
MengX, CuiJ, HeG. Bcl-2 is involved in cardiac hypertrophy through PI3K-Akt pathway. Biomed Res Int, 2021a;2021:6615502; doi: 10.1155/2021/6615502
265.
MengX-Y, ZhangH-Z, RenY-Y, et al.Pinin promotes tumor progression via activating CREB through PI3K/AKT and ERK/MAPK pathway in prostate cancer. Am J Cancer Res, 2021b;11(4):1286–1303.
MicheauO, TschoppJ. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003; 114(2):181–190; doi: 10.1016/S0092-8674(03)00521-X
268.
MichelsJ, KeppO, SenovillaL, et al.Functions of BCL-X L at the interface between cell death and metabolism. Int J Cell Biol, 2013; 2013:705294; doi: 10.1155/2013/705294
269.
MichelsJ, ObristF, VitaleI, et al.MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol, 2014; 92(1):55–61; doi: 10.1016/j.bcp.2014.07.029
270.
MileticAV, JellusovaJ, CatoMH, et al.Essential role for survivin in the proliferative expansion of progenitor and mature B cells. J Immunol, 2016; 196(5):2195–2204; doi: 10.4049/jimmunol.1501690
Minc-GolombD, TsarfatyI, SchwartzJP. Expression of inducible nitric oxide synthase by neurones following exposure to endotoxin and cytokine. Br J Pharmacol, 1994; 112:720–722.
273.
MinhasR, BansalY, BansalG. Inducible nitric oxide synthase inhibitors: A comprehensive update. Med Res Rev, 2020; 40(3):823–855; doi: 10.1002/med.21636
274.
MintzJ, VedenkoA, RoseteO, et al.Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines, 2021; 9(2):94; doi: 10.3390/vaccines9020094
275.
MishraD, PatelV, BanerjeeD. Nitric oxide and S-nitrosylation in cancers: Emphasis on breast cancer. Breast Cancer (Auckl), 2020; 14:1178223419882688; doi: 10.1177/1178223419882688
276.
MitchellDA, MarlettaMA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol, 2005; 1(3):154–158; doi: 10.1038/nchembio720
277.
MittalP, SinghS, SinhaR, et al.Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. Int J Biol Macromol, 2021; 187:999–1018; doi: 10.1016/j.ijbiomac.2021.07.166
278.
MiyashitaT, ReedJC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 1993; 81(1):151–157.
279.
MoncadaS, ErusalimskyJD. Does nitric oxide modulate mitochondrial energy generation and apoptosis?. Nat Rev Mol Cell Biol, 2002; 3(3):214–220; doi: 10.1038/nrm762
280.
MonzóM, RosellR, FelipE, et al.A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol, 1999; 17(7):2100–2104; doi: 10.1200/JCO.1999.17.7.2100
281.
MoriN, FujiiM, ChengG, et al.Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes, 2001; 22(3):279–287; doi: 10.1023/a:1011158021749
282.
MorrisJL, GilletG, PrudentJ, et al.Bcl-2 family of proteins in the control of mitochondrial calcium signalling: An old chap with new roles. Int J Mol Sci, 2021; 22(7):3730; doi: 10.3390/ijms22073730
283.
MottJL, KobayashiS, BronkSF, et al.mir-29 Regulates Mcl-1 protein expression and apoptosis. Oncogene, 2007; 26(42):6133–6140; doi: 10.1038/sj.onc.1210436
284.
MunkhbaatarE, DietzenM, AgrawalD, et al.MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun, 2020; 11(1):4527; doi: 10.1038/s41467-020-18372-1
285.
MusialA, EissaNT. Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem, 2001; 276(26):24268–24273; doi: 10.1074/jbc.M100725200
286.
NakamuraT, OhC, ZhangX, et al.Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration. Free Radic Biol Med, 2021; 172:562–577; doi: 10.1016/j.freeradbiomed.2021.07.002
287.
NakamuraT, WangL, WongCCL, et al.Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell, 2010; 39(2):184–195; doi: 10.1016/j.molcel.2010.07.002
288.
NasuS, YagihashiA, IzawaA, et al.Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002; 22(3):1839–1843.
289.
NeishAS, GewirtzAT, ZengH, et al.Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science, 2000; 289(5484):1560–1563; doi: 10.1126/science.289.5484.1560
290.
NesbittH, BrowneG, O'DonovanKM, et al.Nitric oxide up-regulates RUNX2 in LNCaP prostate tumours: implications for tumour growth in vitro and in vivo. J Cell Physiol, 2016; 231(2):473–482; doi: 10.1002/jcp.25093
291.
NishioE, WatanabeY. Nitric oxide donor-induced apoptosis in smooth muscle cells is modulated by protein kinase C and protein kinase A. Eur J Pharmacol, 1997; 339(2–3):245–251; doi: 10.1016/s0014-2999(97)01368-x
292.
NusslerAK, BilliarTR, HoffmanRA, et al.Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med, 1992; 176:261–264.
293.
O'BrienMA, KirbyR. Apoptosis: A review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care, 2008; 18(6):572–585; doi: 10.1111/j.1476-4431.2008.00363.x
294.
O'ConnorDS, GrossmanD, PlesciaJ, et al.Regulation of apoptosis at cell division by P34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A, 2000; 97(24):13103–13107; doi: 10.1073/pnas.240390697
295.
ObengE. Apoptosis (programmed cell death) and its signals—A review. Braz J Biol, 2020; 81(4):1133–1143; doi: 10.1590/1519-6984.228437
296.
ObermajerN, WongJL, EdwardsRP, et al.Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med, 2013; 210(7):1433–1445; doi: 10.1084/jem.20121277
297.
OdaE, OhkiR, MurasawaH, et al.Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 2000; 288(5468):1053–1058; doi: 10.1126/science.288.5468.1053
298.
OlsonSY, GarbánHJ. Regulation of apoptosis-related genes by nitric oxide in cancer. Nitric Oxide, 2008; 19(2):170–176; doi: 10.1016/j.niox.2008.04.005
299.
OltersdorfT, ElmoreSW, ShoemakerAR, et al.An Inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005; 435(7042):677–681; doi: 10.1038/nature03579
300.
OparinaN, ErlandssonMC, Fäldt BedingA, et al.Prognostic significance of BIRC5/survivin in breast cancer: Results from three independent cohorts. Cancers, 2021; 13(9):2209; doi: 10.3390/cancers13092209
301.
OpfermanJT. Attacking cancer's Achilles heel: Antagonism of anti-apoptotic BCL-2 family members. FEBS J, 2016; 283(14):2661–2675; doi: 10.1111/febs.13472
302.
OyadomariS, TakedaK, TakiguchiM, et al.Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A, 2001; 98(19):10845–10850; doi: 10.1073/pnas.191207498
303.
PalczewskiMB, PetraitisH, ThomasDD. Nitric oxide is an epigenetic regulator of histone post-translational modifications in cancer. Curr Opin Physiol, 2019; 9:94–99; doi: 10.1016/j.cophys.2019.05.006
304.
PanceA. Nitric oxide and hormones in breast cancer: Allies or enemies?. Future Oncol, 2006; 2(2):275–288; doi: 10.2217/14796694.2.2.275
305.
PandeySK, PaulA, Shteinfer-KuzmineA, et al.SMAC/diablo controls proliferation of cancer cells by regulating phosphatidylethanolamine synthesis. Mol Oncol, 2021; 15(11):3037–3061; doi: 10.1002/1878-0261.12959
306.
PannoneG, BufoP, SerpicoR, et al.Survivin phosphorylation and M-phase promoting factor in oral carcinogenesis. Histol Histopathol, 2007; 22(11):1241–1249; doi: 10.14670/HH-22.1241
307.
ParkH-A, LicznerskiP, MnatsakanyanN, et al.Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity. Cell Death Differ, 2017; 24(11):1963–1974; doi: 10.1038/cdd.2017.123
308.
PatelP, MendozaA, RobichauxDJ, et al.Inhibition of the anti-apoptotic Bcl-2 family by BH3 mimetics sensitize the mitochondrial permeability transition pore through Bax and Bak. Front Cell Dev Biol, 2021; 9:765973; doi: 10.3389/fcell.2021.765973
309.
PatelRP, McAndrewJ, SellakH, et al.Biological aspects of reactive nitrogen species. Biochim Biophys Acta, 1999; 1411(2):385–400; doi: 10.1016/S0005-2728(99)00028-6
310.
PautzA, ArtJ, HahnS, et al.Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide, 2010; 23:75–93.
311.
PereiraPMR, EdwardsKJ, MandleywalaK, et al.iNOS regulates the therapeutic response of pancreatic cancer cells to radiotherapy. Cancer Res, 2020; 80(8):1681–1692; doi: 10.1158/0008-5472.CAN-19-2991
312.
PervinS, TranA, TranL, et al.Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase mule increases the stability of Mcl-1 in breast cancer cells. Br J Cancer, 2011; 105(3):428–437; doi: 10.1038/bjc.2011.242
313.
PetrosAM, HuthJR, OostT, et al.Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett, 2010; 20(22):6587–6591; doi: 10.1016/j.bmcl.2010.09.033
314.
PezzellaF, TseAG, CordellJL, et al.Expression of the Bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol, 1990; 137(2):225–232.
PlaczekWJ, WeiJ, KitadaS, et al.A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis, 2010; 1(5):e40; doi: 10.1038/cddis.2010.18
317.
PlenchetteS, RomagnyS, LaurensV, et al.S-nitrosylation in TNF superfamily signaling pathway: Implication in cancer. Redox Biol, 2015; 6:507–515; doi: 10.1016/j.redox.2015.08.019
318.
PlötzM, HossiniAM, GillissenB, et al.Mutual regulation of Bcl-2 proteins independent of the BH3 domain as shown by the BH3-lacking protein Bcl-x(AK). PLoS One, 2012; 7(4):e34549; doi: 10.1371/JOURNAL.PONE.0034549
319.
PobezinskayaYL, LiuZ. The role of TRADD in death receptor signaling. Cell Cycle, 2012; 11(5):871–876; doi: 10.4161/cc.11.5.19300
320.
PoderosoJJ, CarrerasMC, LisderoC, et al.Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys, 1996; 328(1):85–92; doi: 10.1006/abbi.1996.0146
321.
PowanP, ChanvorachoteP. Nitric oxide mediates cell aggregation and mesenchymal to epithelial transition in anoikis-resistant lung cancer cells. Mol Cell Biochem, 2014; 393(1):237–245; doi: 10.1007/s11010-014-2066-7
322.
PrueittRL, BoersmaBJ, HoweTM, et al.Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer, 2007; 120(4):796–805; doi: 10.1002/ijc.22336
323.
PuhakkaARA, HarjuTH, PääkköPK, et al.Nitric oxide synthases are associated with bronchial dysplasia. Lung Cancer, 2006; 51(3):275–282; doi: 10.1016/j.lungcan.2005.11.005
324.
QianS, WeiZ, YangW, et al.The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol, 2022; 12:985363; doi: 10.3389/fonc.2022.985363
325.
QuinnBA, DashR, AzabB, et al.Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs, 2011; 20(10):1397–1411; doi: 10.1517/13543784.2011.609167
326.
RameshP, LannaganTRM, JackstadtR, et al.BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differ, 2021; 28(12):3282–3296; doi: 10.1038/s41418-021-00816-w
327.
ReedJC. Dysregulation of apoptosis in cancer. J Clin Oncol, 1999; 17(9):2941–2953; doi: 10.1200/jco.1999.17.9.2941
328.
ReedJC, CuddyM, SlabiakT, et al.Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature, 1988; 17;336(6196):259–261; doi: 10.1038/336259a0
329.
ReedJC, MeisterL, TanakaS, et al.Differential expression of Bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res, 1991; 15;51(24):6529–6538.
330.
RenY, HanX, YuK, et al.microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol Med Rep, 2014; 10(1):315–321; doi: 10.3892/mmr.2014.2222
331.
RennerO, MayerM, LeischnerC, et al.Systematic review of gossypol/AT-101 in cancer clinical trials. Pharmaceuticals, 2022; 15(2):144; doi: 10.3390/ph15020144
332.
RiedlSJ, RenatusM, SchwarzenbacherR, et al.Structural basis for the inhibition of caspase-3 by XIAP. Cell, 2001; 104(5):791–800; doi: 10.1016/S0092-8674(01)00274-4
333.
RobertsAW, DavidsMS, PagelJM, et al.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med, 2016; 374(4):311–322; doi: 10.1056/NEJMoa1513257
334.
Rodríguez-MartínE, CasarejosMJ, BazánE, et al.Nitric oxide induces differentiation in the NB69 human catecholamine-rich cell line. Neuropharmacology, 2000; 39(11):2090–2100; doi: 10.1016/S0028-3908(00)00049-6
335.
RohJ, ChoH, PakHK, et al.BCL2 super-expressor diffuse large B-cell lymphoma: A distinct subgroup associated with poor prognosis. Mod Pathol, 2021; 35(4):480–488; doi: 10.1038/s41379-021-00962-z
336.
RomagnyS, BouaouicheS, LucchiG, et al.S-nitrosylation of CIAP1 switches cancer cell fate from TNFα/TNFR1-mediated cell survival to cell death. Cancer Res, 2018; 78(8):1948–1957; doi: 10.1158/0008-5472.CAN-17-2078
337.
RosserCJ, ReyesAO, Vakar-LopezF, et al.Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol, 2003; 56(1):1–6; doi: 10.1016/S0360-3016(02)04468-1
338.
RossigL, HaendelerJ, HermannC, et al.Nitric oxide down-regulates MKP-3 mRNA levels: Involvement in endothelial cell protection from apoptosis. J Biol Chem, 2000; 275(33):25502–25507; doi: 10.1074/JBC.M002283200
339.
RudinCM, BrambillaE, Faivre-FinnC, et al.Small-cell lung cancer. Nat Rev Dis Primer, 2021; 7(1):1–20; doi: 10.1038/s41572-020-00235-0
340.
SaedGM, Ali-FehmiR, JiangZL, et al.Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol, 2010; 116(2):276–281; doi: 10.1016/j.ygyno.2009.11.004
341.
SafaAR. Roles of C-FLIP in apoptosis, necroptosis, and autophagy. J Carcinog Mutagen, 2013;(Suppl 6):003; doi: 10.4172/2157-2518.S6-003
342.
SafaAR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci, 2020; 6(3):341; doi: 10.15761/jts.1000341
343.
SaligramaPT, FortnerKA, SecinaroMA, et al.IL-15 maintains T-cell survival via S-nitrosylation-mediated inhibition of caspase-3. Cell Death Differ, 2014; 21(6):904–914; doi: 10.1038/cdd.2014.10
344.
SalveminiD, KimSF, MollaceV. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: Relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol, 2013; 304(7):R473–R487; doi: 10.1152/ajpregu.00355.2012
345.
SalvesenGS, DuckettCS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol, 2002; 3(6):401–410; doi: 10.1038/nrm830
346.
SanaJ, FaltejskovaP, SvobodaM, et al.Novel classes of non-coding RNAs and cancer. J Transl Med, 2012; 10:103; doi: 10.1186/1479-5876-10-103
347.
SarelaAI, MacadamRC, FarmerySM, et al.Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut, 2000; 46(5):645–650; doi: 10.1136/gut.46.5.645
SchwickartM, HuangX, LillJR, et al.Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010; 463(7277):103–107; doi: 10.1038/nature08646
355.
SethiG, AhnKS, AggarwalBB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: Role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res, 2008; 6(6):1059–1070; doi: 10.1158/1541-7786.MCR-07-2088
356.
ShackaJJ, GarnerMA, GonzalezJD, et al.Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. Cell Death Differ, 2006; 13(9):1506–1514; doi: 10.1038/sj.cdd.4401831
357.
ShahG, ZhangG, ChenF, et al.iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. Urol Oncol, 2014; 32(1):45.e1–45.e9; doi: 10.1016/j.urolonc.2013.06.005
358.
ShaharN, LarischS. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat, 2020; 52:100712; doi: 10.1016/j.drup.2020.100712
359.
SheltonJ, LuX, HollenbaughJA, et al.Biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs. Chem Rev, 2016; 116(23):14379–14455; doi: 10.1021/acs.chemrev.6b00209
360.
ShenX, BurguillosMA, OsmanAM, et al.Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype. Nat Immunol, 2016; 17(11):1282–1290; doi: 10.1038/ni.3545
361.
ShimizuS, TakeharaT, HikitaH, et al.The Let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol, 2010; 52(5):698–704; doi: 10.1016/j.jhep.2009.12.024
362.
ShinS, SungBJ, ChoYS, et al.An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001; 40(4):1117–1123; doi: 10.1021/bi001603q
363.
Shirane-KitsujiM, NakayamaKI. Mitochondria: FKBP38 and mitochondrial degradation. Int J Biochem Cell Biol, 2014; 51:19–22; doi: 10.1016/j.biocel.2014.03.007
364.
ShirleyS, MicheauO. Targeting C-FLIP in cancer. Cancer Lett, 2013; 332(2):141–150; doi: 10.1016/j.canlet.2010.10.009
365.
ShlyakhtinaY, PavetV, GronemeyerH. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis, 2017; 8(8):3025; doi: 10.1038/cddis.2017.423
SimeoneA-M, EkmekciogluS, BroemelingLD, et al.A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: The production of nitric oxide. Mol Cancer Ther, 2002; 1(12):1009–1017.
368.
SinghA, SpitzerMH, JoyJP, et al.Postmitotic G1 phase survivin drives mitogen-independent cell division of B lymphocytes. Proc Natl Acad Sci U S A, 2022; 119(18):e2115567119; doi: 10.1073/pnas.2115567119
369.
SinghI, KimJ, SinghAK, et al.STAT3 regulation by S-nitrosylation: Implication in cancer. Redox Biol, 2015; 5:416–417; doi: 10.1016/j.redox.2015.09.021
370.
SinghR, LetaiA, SarosiekK. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol, 2019; 20(3):175–193; doi: 10.1038/s41580-018-0089-8
371.
SinghS, GuptaAK. Nitric oxide: Role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol, 2011; 67(6):1211–1224; doi: 10.1007/s00280-011-1654-4
372.
SinicropeFA, HartJ, MichelassiF, et al.Prognostic value of Bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res, 1995; 1(10):1103–1110.
373.
SnyderCM, ShroffEH, LiuJ, et al.Nitric oxide induces cell death by regulating anti-apoptotic BCL-2 family members. pLoS One, 2009; 4(9):e7059; doi: 10.1371/journal.pone.0007059
374.
SoccoS, BoveeRC, PalczewskiMB, et al.Epigenetics: The third pillar of nitric oxide signaling. Pharmacol Res, 2017; 121:52–58; doi: 10.1016/j.phrs.2017.04.011
375.
SomasundaramV, BasudharD, BharadwajG, et al.Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxid Redox Signal, 2019; 30(8):1124–1143; doi: 10.1089/ars.2018.7527
376.
SongJ, SoT, ChengM, et al.Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity, 2005; 22(5):621–631; doi: 10.1016/j.immuni.2005.03.012
377.
SouersAJ, LeversonJD, BoghaertER, et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med, 2013; 19(2):202–208; doi: 10.1038/nm.3048
378.
SoundararajanL, DharmarajanA, SamjiP. Regulation of pleiotropic physiological roles of nitric oxide signaling. Cell Signal, 2023; 101:110496; doi: 10.1016/j.cellsig.2022.110496
379.
SpiegelA, HundleyTR, ChenJ, et al.NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol, 2005; 70(7):993–1000; doi: 10.1016/j.bcp.2005.06.027
380.
SquadritoGL, PryorWA. Oxidative chemistry of nitric oxide: The roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med, 1998; 25:392–403.
381.
SrinivasulaSM, HegdeR, SalehA, et al.A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature, 2001; 410(6824):112–116; doi: 10.1038/35065125
382.
StamlerJ. Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell, 1994; 78:931–936.
StevensM, OlteanS. Modulation of the apoptosis gene Bcl-x function through alternative splicing. Front Genet, 2019; 10:804; doi: 10.3389/FGENE.2019.00804/BIBTEX
385.
StrasserA, VauxDL. Viewing BCL2 and cell death control from an evolutionary perspective. Cell Death Differ, 2018; 25(1):13–20; doi: 10.1038/cdd.2017.145
386.
SuS-H, JenCJ, ChenH. NO signaling in exercise training-induced anti-apoptotic effects in human neutrophils. Biochem Biophys Res Commun, 2011; 405(1):58–63; doi: 10.1016/j.bbrc.2010.12.123
387.
SubapriyaR, KumaraguruparanR, RamachandranCR, et al.Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem, 2002; 35:489–493.
388.
SuiX, ChenR, WangZ, et al.Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis, 2013; 4(10):e838; doi: 10.1038/cddis.2013.350
389.
SunH, KapuriaV, PetersonLF, et al.Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 2011a;117(11):3151–3162; doi: 10.1182/blood-2010-03-276477
390.
SunQ, WangY, DesgrosellierJS. Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells. Cancer Lett, 2019; 457:40–46; doi: 10.1016/j.canlet.2019.05.004
391.
SunT, SunB, ZhaoX, et al.Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: A study of hepatocellular carcinoma. Hepatology, 2011b;54(5):1690–1706; doi: 10.1002/hep.24543
392.
SupSJ, AlemañyCA, PohlmanB, et al.Expression of Bcl-2 in classical Hodgkin's lymphoma: An independent predictor of poor outcome. J Clin Oncol, 2005; 23(16):3773–3779; doi: 10.1200/JCO.2005.04.358
393.
SušacI, OzretićP, GregorićM, et al.Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients. J Oncol, 2019; 2019:3483192; doi: 10.1155/2019/3483192
394.
SuvarnaV, SinghV, MurahariM. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur J Pharmacol, 2019; 862:172655; doi: 10.1016/j.ejphar.2019.172655
395.
SwanaHS, SmithSD, PerrottaPL, et al.Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol, 1999; 161(2):630–634.
396.
SwitzerCH, ChengRY, RidnourLA, et al.Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res, 2012; 12;14(5):R125; doi: 10.1186/bcr3319
397.
SzaboC. Gasotransmitters in cancer: From pathophysiology to experimental therapy. Nat Rev Drug Discov, 2016; 15(3):185–203; doi: 10.1038/nrd.2015.1
398.
TabuchiY, MatsuokaJ, GunduzM, et al.Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol, 2009; 34(2):313–319; doi: 10.3892/IJO_00000153/HTML
399.
TamataniM, OgawaS, NuñezG, et al.Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ, 1998; 5(10):911–919; doi: 10.1038/sj.cdd.4400439
400.
TammI, WangY, SausvilleE, et al.IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 1998; 58(23):5315–5320.
401.
TanakaK, IwamotoS, GonG, et al.Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res, 2000; 6(1):127–134.
402.
TazawaH, TsuchiyaN, IzumiyaM, et al.Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A, 2007; 104(39):15472–15477; doi: 10.1073/pnas.0707351104
403.
TenganCH, MoraesCT. NO control of mitochondrial function in normal and transformed cells. Biochim Biophys Acta, 2017; 1858(8):573–581; doi: 10.1016/j.bbabio.2017.02.009
404.
ThomasD, RidnourL, IsenbergJ, et al.The chemical biology of nitric oxide: Implications in cellular signaling. Free Radic Biol Med, 2008; 45:18–31.
405.
ThomasDD, WinkDA. NOS2 as an emergent player in progression of cancer. Antioxid Redox Signal, 2017; 26(17):963–965; doi: 10.1089/ars.2016.6835
406.
ThomasS, QuinnBA, DasSK, et al.Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets, 2013; 17(1):61–75; doi: 10.1517/14728222.2013.733001
407.
ThomsenLL, LawtonFG, KnowlesRG, et al.Nitric oxide synthase activity in human gynecological cancer. Cancer Res, 1994; 54(5):1352–1354.
408.
ThomsenLL, MilesDW, HapperfieldL, et al.Nitric oxide synthase activity in human breast cancer. Br J Cancer, 1995; 72(13):41–44.
409.
TianH, WangJ, ZhangB, et al.MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation involved in cancer cell apoptosis. pLoS One, 2012; 7(5):e37200; doi: 10.1371/journal.pone.0037200
410.
TörökNJ, HiguchiH, BronkS, et al.Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 91. Cancer Res, 2002; 62(6):1648–1653.
411.
TrisciuoglioD, TuponeMG, DesideriM, et al.BCL-XL overexpression promotes tumor progression-associated properties. Cell Death Dis, 2017; 8(12):3216; doi: 10.1038/s41419-017-0055-y
412.
TsangAHK, LeeY-I, KoHS, et al.S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A, 2009; 106(12):4900–4905; doi: 10.1073/pnas.0810595106
413.
TsubakiM, OgawaN, TakedaT, et al.Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP. Biomed Pharmacother, 2014; 68(8):999–1005; doi: 10.1016/j.biopha.2014.09.009
414.
TsujimotoY, CossmanJ, JaffeE, et al.Involvement of the Bcl-2 gene in human follicular lymphoma. Science, 1985; 228(4706):1440–1443; doi: 10.1126/science.3874430
415.
TzengE, BilliarTR, RobbinsPD, et al.Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A, 1995; 92(25):11771–11775; doi: 10.1073/pnas.92.25.11771
416.
UllrichV, KissnerR. Redox signaling: Bioinorganic chemistry at its best. J Inorg Biochem, 2006; 100(12):2079–2086; doi: 10.1016/J.JINORGBIO.2006.09.019
417.
VakkalaM, KahlosK, LakariE, et al.Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res, 2000; 6(6):2408–2416.
418.
van LooG, van GurpM, DepuydtB, et al.The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ, 2002; 9(1):20–26; doi: 10.1038/sj.cdd.4400970
419.
VaniniF, KashfiK, NathN. The dual role of iNOS in cancer. Redox Biol, 2015; 6:334; doi: 10.1016/J.REDOX.2015.08.009
420.
VasudevanD, BoveeRC, ThomasDD. Nitric oxide, the new architect of epigenetic landscapes. Nitric Oxide Biol Chem, 2016; 59:54–62; doi: 10.1016/j.niox.2016.08.002
421.
VasudevanD, HickokJR, BoveeRC, et al.Nitric oxide regulates gene expression in cancers by controlling histone posttranslational modifications. Cancer Res, 2015; 15;75(24):5299–5308; doi: 10.1158/0008-5472.CAN-15-1582
422.
VauxDL, CoryS, AdamsJM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-Myc to immortalize pre-B cells. Nature, 1988; 335(6189):440–442; doi: 10.1038/335440a0
423.
VossAK, StrasserA. The essentials of developmental apoptosis. F1000Res, 2020; 9:F1000 Faculty Rev-148; doi: 10.12688/f1000research.21571.1
424.
WajantH. The Fas signaling pathway: More than a paradigm. Science, 2002; 296(5573):1635–1636; doi: 10.1126/science.1071553
425.
WajantH, SiegmundD. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front Cell Dev Biol, 2019; 7:91; doi: 10.3389/fcell.2019.00091
426.
WalczakH. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol, 2013; 5(5):a008698; doi: 10.1101/cshperspect.a008698
427.
WangH, GuoM, WeiH, et al.Targeting MCL-1 in cancer: Current status and perspectives. J Hematol Oncol, 2021; 14(1):67; doi: 10.1186/s13045-021-01079-1
428.
WangH, MacNaughtonWK. Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res, 2005; 1;65(19):8604–8607; doi: 10.1158/0008-5472.CAN-05-1169
429.
WangH, WangL, XieZ, et al.Nitric oxide (NO) and NO synthases (NOS)-based targeted therapy for colon cancer. Cancers, 2020; 12(7):1881; doi: 10.3390/cancers12071881
430.
WangJ, HeP, GaidaM, et al.Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget, 2016; 7(33):52993–53004; doi: 10.18632/oncotarget.10323
431.
WangJ, WuM-Y, SuH, et al.iNOS interacts with autophagy receptor p62 and is degraded by autophagy in macrophages. Cells, 2019; 8(10):1255; doi: 10.3390/cells8101255
432.
WangK, BremsJJ, GamelliRL, et al.iNOS/NO signaling regulates apoptosis induced by glycochenodeoxycholate in hepatocytes. Cell Signal, 2011a;23(10):1677–1685; doi: 10.1016/j.cellsig.2011.06.003
433.
WangL, ZhengY, GaoX, et al.Retinoid X receptor ligand regulates RXRα/Nur77-dependent apoptosis via modulating its nuclear export and mitochondrial targeting. Int J Clin Exp Pathol, 2017; 10(11):10770–10780.
434.
WangP, ZhenH, ZhangJ, et al.Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog, 2012; 51(7):586–595; doi: 10.1002/mc.20829
435.
WangQ, WuPC, RobersonRS, et al.Survivin and escaping in therapy-induced cellular senescence. Int J Cancer, 2011b;128(7):1546–1558; doi: 10.1002/ijc.25482
436.
WangZ. Protein S-nitrosylation and cancer. Cancer Lett, 2012; 320:123–129.
437.
WardRA, FawellS, Floc'hN, et al.Challenges and opportunities in cancer drug resistance. Chem Rev, 2021; 121(6):3297–3351; doi: 10.1021/acs.chemrev.0c00383
438.
WarrenCFA, Wong-BrownMW, BowdenNA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis, 2019; 21;10(3):177; doi: 10.1038/s41419-019-1407-6
439.
WarrierNM, AgarwalP, KumarP. Emerging importance of survivin in stem cells and cancer: The development of new cancer therapeutics. Stem Cell Rev Rep, 2020; 16(5):828–852; doi: 10.1007/s12015-020-09995-4
440.
WeiAH, RobertsAW, SpencerA, et al.Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Rev, 2020; 44:100672; doi: 10.1016/j.blre.2020.100672
441.
WeiJ, StebbinsJL, KitadaS, et al.BI-97C1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, 2010; 53(10):4166–4176; doi: 10.1021/jm1001265
442.
WeimingXU, LiuLZ, LoizidouM, et al.The role of nitric oxide in cancer. Cell Res, 2002; 12:311–320.
443.
WeissLM, WarnkeRA, SklarJ, et al.Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med, 1987; 317(19):1185–1189; doi: 10.1056/NEJM198711053171904
444.
WellerM, MalipieroU, AguzziA, et al.Protooncogene Bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest, 1995; 95(6):2633–2643; doi: 10.1172/JCI117965
445.
WenQ, ZhanY, ZhengH, et al.Elevated expression of Mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer. Diagn Pathol, 2019; 14(1):108; doi: 10.1186/s13000-019-0884-3
446.
WheatleySP, AltieriDC. Survivin at a glance. J Cell Sci, 2019; 132(7):jcs223826; doi: 10.1242/jcs.223826
447.
WiddenH, PlaczekWJ. The multiple mechanisms of MCL1 in the regulation of cell fate. Commun Biol, 2021; 4(1):1–12; doi: 10.1038/s42003-021-02564-6
448.
WilsonBE, MochonE, BoxerLM. Induction of Bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol, 1996; 16(10):5546–5556; doi: 10.1128/MCB.16.10.5546
449.
WinderML, CampbellKJ. MCL-1 is a clinically targetable vulnerability in breast cancer. Cell Cycle Georget Tex, 2022; 21(14):1439–1455; doi: 10.1080/15384101.2022.2054096
450.
WinkDA, CookJA, ChristodoulouD, et al.Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide, 1997; 1(1):88–94; doi: 10.1006/niox.1996.0108
451.
WongJC, BathinaM, FiscusRR. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J Cell Biochem, 2012; 113(11):3587–3598; doi: 10.1002/jcb.24237
452.
WoodKC. Mapping the pathways of resistance to targeted therapies. Cancer Res, 2015; 75(20):4247–4251; doi: 10.1158/0008-5472.CAN-15-1248
453.
WuW, WanOW, ChungKKK. S-nitrosylation of XIAP at Cys 213 of BIR2 domain impairs XIAP's anti-caspase 3 activity and anti-apoptotic function. Apoptosis, 2015; 20(4):491–499; doi: 10.1007/s10495-015-1087-3
454.
XiaZ, DickensM, RaingeaudJ, et al.Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995; 270(5240):1326–1331; doi: 10.1126/science.270.5240.1326
455.
XiaoW, XuZ, ChangS, et al.Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. Cancer Lett, 2019; 444:45–59; doi: 10.1016/J.CANLET.2018.12.014
456.
XieK, HuangS, DongZ, et al.Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst, 1997; 89(6):421–427; doi: 10.1093/jnci/89.6.421
457.
XieQW, KashiwabaraY, NathanC. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem, 1994; 269(7):4705–4708.
458.
XiongH, ZhuC, LiF, et al.Inhibition of interleukin-12 p40 transcription and NF-kappaB activation by nitric oxide in murine macrophages and dendritic cells. J Biol Chem, 2004; 279(11):10776–10783; doi: 10.1074/jbc.M313416200
459.
XuD, WangQ, AnY, et al.MiR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting survivin. Mol Med Rep, 2013; 8(2):379–384; doi: 10.3892/mmr.2013.1504
460.
XuY, FangF, LudewigG, et al.A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol, 2004; 23(9):527–537; doi: 10.1089/dna.2004.23.527
461.
XueQ, YanY, ZhangR, et al.Regulation of iNOS on immune cells and its role in diseases. Int J Mol Sci, 2018; 19(12):3805; doi: 10.3390/ijms19123805.
462.
YangG, RosenDG, LiuG, et al.CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res, 2010; 16(15):3875–3886; doi: 10.1158/1078-0432.CCR-10-0483/83486/AM/CXCR2-PROMOTES-OVARIAN-CANCER-GROWTH-THROUGH
463.
YangL, WangY, GuoL, et al.The expression and correlation of iNOS and p53 in oral squamous cell carcinoma. Biomed Res Int, 2015; 2015:637853; doi: 10.1155/2015/637853
464.
YangX-K, ZhengF, ChenJ-H, et al.[Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line] [in Chinese]. Ai Zheng, 2002; 21(12):1288–1291.
465.
YangY, LiS, SunY, et al.Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. Onco Targets Ther, 2019; 12:897–906; doi: 10.2147/OTT.S187015
466.
YeciesD, CarlsonNE, DengJ, et al.Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 2010; 22;115(16):3304–3313; doi: 10.1182/blood-2009-07-233304
467.
YinXY, JiangJM, LiuJY, et al.Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice. World J Gastroenterol, 2007; 14;13(46):6249–6253; doi: 10.3748/wjg.v13.i46.6249
468.
YingL, HofsethAB, BrowningDD, et al.Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res, 2007; 67(19):9286–9293; doi: 10.1158/0008-5472.CAN-07-2238
469.
YooY-M, JungE-M, AhnC, et al.Nitric oxide prevents H2O2-induced apoptosis in SK-N-MC human neuroblastoma cells. Int J Biol Sci, 2018; 14(14):1974–1984; doi: 10.7150/ijbs.28050
470.
YuJ, ChenL-H, ZhangB, et al.The modulation of endometriosis by lncRNA MALAT1 via NF-κB/INOS. Eur Rev Med Pharmacol Sci, 2019; 23(10):4073–4080; doi: 10.26355/eurrev_201905_17908
471.
YuJ, WangZ, ZhangH, et al.Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma. World J Gastroenterol, 2021; 27(43):7546–7562; doi: 10.3748/wjg.v27.i43.7546
472.
YuZ, GuoJ, MengT, et al.Bcl-xL DNAzymes promote radiosensitivity and chemosensitivity in colorectal cancer cells via enhancing apoptosis. BMC Pharmacol Toxicol, 2022; 23(1):13; doi: 10.1186/s40360-022-00553-x
473.
ZamanS, WangR, GandhiV. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma, 2014; 55(9):1980–1992; doi: 10.3109/10428194.2013.855307
474.
ZarogoulidisP, PetanidisS, KioseoglouE, et al.MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and survivin in lung cancer cells. Cell Signal, 2015; 27(8):1576–1588; doi: 10.1016/J.CELLSIG.2015.04.009
475.
ZechB, WilmM, van EldikR, et al.Mass spectrometric analysis of nitric oxide-modified caspase-3. J Biol Chem, 1999; 274(30):20931–20936; doi: 10.1074/jbc.274.30.20931
476.
ZhangB, LengC, WuC, et al.Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol Rep, 2016a;35(3):1807–1815; doi: 10.3892/or.2015.4479
477.
ZhangD, ZhaoN, MaB, et al.Procaspase-9 induces its cleavage by transnitrosylating XIAP via the thioredoxin system during cerebral ischemia-reperfusion in rats. Sci Rep, 2016b;6(1):24203; doi: 10.1038/srep24203
478.
ZhangH, NimmerPM, TahirSK, et al.Bcl-2 family proteins are essential for platelet survival. Cell Death Differ, 2007; 14(5):943–951; doi: 10.1038/sj.cdd.4402081
479.
ZhangH, RosdahlI. Bcl-xL and Bcl-2 proteins in melanoma progression and UVB-induced apoptosis. Int J Oncol, 2006; 28(3):661–666.
480.
ZhangL, LiuJ, WangX, et al.Upregulation of cytoskeleton protein and extracellular matrix protein induced by stromal-derived nitric oxide promotes lung cancer invasion and metastasis. Curr Mol Med, 2014; 14(6):762–771; doi: 10.2174/1566524014666140724103147
481.
ZhangL, LuZ, ZhaoX. Targeting Bcl-2 for cancer therapy. Biochim Biophys Acta Rev Cancer, 2021; 1876(1):188569; doi: 10.1016/j.bbcan.2021.188569
482.
ZhangX, JinL, TianZ, et al.Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma. Cancer Sci, 2019a;110(3):1054–1063; doi: 10.1111/cas.13945
483.
ZhangYL, PangLQ, WuY, et al.Significance of Bcl-xL in human colon carcinoma. World J Gastroenterol, 2008; 21;14(19):3069–3073; doi: 10.3748/wjg.14.3069
484.
ZhangYX, WangH, RenC, et al.Correlation between C-MYC, BCL-2, and BCL-6 protein expression and gene translocation as biomarkers in diagnosis and prognosis of diffuse large B-cell lymphoma. Front Pharmacol, 2019b;9:1497; doi: 10.3389/FPHAR.2018.01497/BIBTEX
485.
ZhaoP, MengQ, LiuL-Z, et al.Regulation of survivin by PI3K/Akt/P70S6K1 pathway. Biochem Biophys Res Commun, 2010; 395(2):219–224; doi: 10.1016/j.bbrc.2010.03.165
ZhengP, ChenQ, TianX, et al.DNA damage triggers tubular endoplasmic reticulum extension to promote apoptosis by facilitating ER-mitochondria signaling. Cell Res, 2018; 28(8):833–854; doi: 10.1038/s41422-018-0065-z
488.
ZhongS, YuD, WangY, et al.An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol, 2010; 49(1):91–99; doi: 10.3109/02841860903246557
489.
ZhouL, ZhaoY. B7-H3 induces ovarian cancer drugs resistance through an PI3K/AKT/BCL-2 signaling pathway. Cancer Manag Res, 2019; 11:10205; doi: 10.2147/CMAR.S222224
490.
ZhouP, QianL, KozopasKM, et al.Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood, 1997; 89(2):630–643.
491.
ZhouX, LinC. Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: A systematic review and meta-analysis. World J Surg Oncol, 2015; 13(1):27; doi: 10.1186/s12957-015-0461-5
492.
ZhouX-D, YuJ-P, LiuJ, et al.Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin Sci (Lond), 2004; 106(4):397–405; doi: 10.1042/CS20030238
493.
ZichanH, LinfeiJ, JinliangW, et al.MicroRNA-294 regulates apoptosis of the porcine cerebellum caused by selenium deficiency via targeting iNOS. Biol Trace Elem Res, 2021; 199(12):4593–4603; doi: 10.1007/s12011-021-02583-8
494.
ZongH, YinB, ChenJ, et al.Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med, 2009; 217(3):203–208; doi: 10.1620/tjem.217.203
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
